Enzon Pharmaceuticals Inc http://www.alacrastore.com/company-snapshot/Enzon_Pharmaceuticals_Inc-1005698 Saturday, November 22, 2008 9:41:51 AM 1005698 Enzon Pharmaceuticals Inc en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/B2011688ccbn/B2011688norm...Results were adjusted for costs associated with ongoing strategic initiatives, including cost for potential sale of specialty pharma business and spin-off of biotech. ... 11/5/2008 1:07:00 PMEnzon Pharmaceuticals, Inc.54.0000EditedEnzon Pharmaceuticals, Inc. Q3 2008 Earnings Conference Call SummaryENZN9:00am ETBriefB2011688Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2011688ccbn/T2011688norm...Good morning, ladies and gentlemen. Welcome to the Enzon Pharmaceuticals third-quarter earnings conference call. Following the presentation, we will conduct a question-and-answer session. (OPERATOR INSTRUCTIONS) As a reminder this, conference is being recorded today, November #, ####. I would now like to turn the meeting over to Craig Tooman, Chief Financial Officer. Please go ahead, sir. ... 11/5/2008 10:05:00 AMEnzon Pharmaceuticals, Inc.54.0000FinalEnzon Pharmaceuticals, Inc. Q3 2008 Earnings Conference Call TranscriptENZN9:00am ETTranscriptT2011688Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-29049897newstex/BW-0001-29049897xml Oct. ##, #### (Business Wire) -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended September ##, ####, on Wednesday, November #, #### at approximately #:## am...040000000401600004016018040160480401600107000000070140000701401210/29/2008 9:25:36 AM180000001800800018004000Business WireBW-0001-29049897ENZON PHARMACEUTICALS INCCRAIG A TOOMANJEFFREY H BUCHALTERENZNNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1912657ccbn/B1912657norm...Oncaspar growing nicely in units and dollars; sales and marketing team have nice platform for sustainable growth. ... 8/6/2008 11:06:00 AMEnzon Pharmaceuticals, Inc.54.0000EditedEnzon Pharmaceuticals, Inc. Q2 2008 Earnings Conference Call SummaryENZN9:00am ETBriefB1912657Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1912657ccbn/T1912657norm...Good morning, ladies and gentlemen. Thank you for holding. Welcome to Enzon Pharmaceuticals' second-quarter earnings conference call. At this time all participants are in a listen-only mode. There will be a question-and-answer session to follow. (OPERATOR INSTRUCTIONS) Please be advised that this call is being recorded at the Company's request. And at this time I would like to introduce your host for today's call, Mr. Craig Tooman, Executive Vice President of Finance and Chief Financial Officer of Enzon Pharmaceuticals. Please go ahead. ... 8/6/2008 10:06:00 AMEnzon Pharmaceuticals, Inc.54.0000FinalEnzon Pharmaceuticals, Inc. Q2 2008 Earnings Conference Call TranscriptENZN9:00am ETTranscriptT1912657Credit & Investment ResearchThomson StreetEventsUS - Enzon Pharmaceuticals Inc, a biotechnology company, planned to spin off its novel biotechnology business unit, to its shareholders. The transaction was subject to customary closing conditions, board and regulatory approvals.5/8/2008 4:42:47 PM81949M29657C81949M293904ShareholdersEnzon Pharmaceuticals Inc- Novel Biotechnology BusinessShareholdersEnzon Pharmaceuticals Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Enzon_Pharmaceuticals_Inc_spins_off_Enzon_Pharms_Inc_Novel_Biotech-1975762020sdc/19757620201975762020Copyright © 2008, Thomson Financial, All Rights ReservedInvestment & Commodity Firms,Dealers,ExchangesUnited StatesInvestors, nec6799UNUnknownPrivate6799:Investors, nec6799:Investors, necDrugsUnited StatesBiological products, except diagnostic substances2836NJNew JerseySubsidiary139634001Investor groupBiotechnology coNot ApplicableCommon Stock1009493001May 8 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.00000Investor groupInvestor groupInvestor group1.000002.000003.000004.000005.00000Novel biotechnology businessof Enzon Pharmaceuticals Incdevelops and enhancestherapeutics forlife-threatening diseases.Novel biotechnology business of Enzon Pharmaceuticals Incdevelops and enhances therapeutics for life-threateningdiseases.Novel biotechnology business of Enzon Pharmaceuticals Inc develops and enhances therapeutics for life-threatening diseases.0.000000.000000.000000.00000N07 May 08Wed, 07 May 2008 00:00:00 ESTDate Announced: 05/07/2008Date Effective:AcquisitionNot Appl.0.000000.000000.000000.000000.000000.00000Price/Share0.0000000.000000.0000000.000000.000000.000000.000000.000000.0000000.00000N0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.00000US - Enzon PharmaceuticalsInc, a biotechnology company,planned to spin off its novelbiotechnology business unit,to its shareholders. Thetransaction was subject tocustomary closing conditions,board and regulatoryapprovals.US - Enzon Pharmaceuticals Inc, a biotechnology company, planned to spin off its novel biotechnology business unit, to its shareholders. The transaction was subject to customary closing conditions, board and regulatory approvals.US - Enzon Pharmaceuticals Inc, a biotechnology company, planned to spin off its novelbiotechnology business unit, to its shareholders. The transaction was subject to customaryclosing conditions, board and regulatory approvals.US - Enzon Pharmaceuticals Inc, a biotechnology company, planned to spin off its novel biotechnology business unit, to its shareholders. The transaction was subject to customary closing conditions,board and regulatory approvals.US - Enzon Pharmaceuticals Inc, a biotechnology company, planned to spin off its novel biotechnology business unit, to its shareholders.The transaction was subject to customary closing conditions, board and regulatory approvals.Goldman Sachs & Co1.00000$ 0.000 - Goldman Sachs & Co - Adv0.00000Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations139634001Unknown6799UnknownPrivate2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations14341002NasdaqUnited States2836New JerseyPublicENZN0.000000.000000.000000.00000Skadden, Arps, Slate, Meagher & FlomDeal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/ccbn/B1840171ccbn/B1840171norm...Significantly reduced outstanding debt balance due July, #### to $##.#m, ahead of required timeline. ... 5/7/2008 12:08:00 PMEnzon Pharmaceuticals, Inc.54.0000EditedQ1 2008 Enzon Pharmaceuticals, Inc. Earnings Conference Call SummaryENZN10:00am ETBriefB1840171Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1840171ccbn/T1840171norm...Welcome to Enzon Pharmaceuticals' first quarter earnings conference call. (OPERATOR INSTRUCTIONS) Following the presentation we will conduct a question-and-answer session. (OPERATOR INSTRUCTIONS) Please be advised that this call is being recorded at the company's request. At this time, I would like to introduce your host for today's call, Craig Tooman, Executive Vice President of Finance and Chief Financial Officer of Enzon Pharmaceuticals. Please go ahead, sir. ... 5/7/2008 11:06:00 AMEnzon Pharmaceuticals, Inc.54.0000FinalQ1 2008 Enzon Pharmaceuticals, Inc. Earnings Conference Call TranscriptENZN10:00am ETTranscriptT1840171Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1762942ccbn/B1762942normQ# #### Enzon Pharmaceuticals, Inc. Earnings Conference Call2/14/2008 3:18:01 PMEnzon Pharmaceuticals, Inc.106.0000EditedQ4 2007 Enzon Pharmaceuticals, Inc. Earnings Conference Call SummaryENZN9:00am ETBriefB1762942Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1762942ccbn/T1762942normQ# #### Enzon Pharmaceuticals, Inc. Earnings Conference Call2/14/2008 10:06:00 AMEnzon Pharmaceuticals, Inc.106.0000FinalQ4 2007 Enzon Pharmaceuticals, Inc. Earnings Conference Call TranscriptENZN9:00am ETTranscriptT1762942Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/srp/21618srp/21618norm...Address:### Route ###/###, Bridgewater, New Jersey ##### Incorporated:DelawareWeb Site: www.enzon.comSIC Classification: Biological Products, Except Diagnostic Substances (####) Business Description: Enzon Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures and markets human therapeutics for life-threatening diseases on its own and through strategic partnerships. Indices:Russell ####, Russell #### ... 21618293904108ENZN10/6/2006 12:23:00 PM21618Credit & Investment ResearchSharkRepellent.net